Piedmont Biosciences

Piedmont Biosciences is a veterinary biotechnology company based in Athens, Georgia, that specializes in the development of innovative pharmaceutical products for companion animals. The company focuses on repurposing and reformulating proven human and animal drugs using proprietary delivery technologies to improve efficacy, safety, and ease of administration. Its primary therapeutic areas include pain management, sedation, and parasitology, with a strong track record of achieving FDA Center for Veterinary Medicine (CVM) approvals. In July 2022, the company's commercial arm, Piedmont Animal Health, was acquired by Dechra Pharmaceuticals for $210 million. This acquisition integrated Piedmont's late-stage pipeline and approved products, such as Zenalpha and Okuvia, into Dechra's global portfolio.